BrightEdge LLC, the American Cancer Society’s venture capital and impact investment arm, has released its annual report highlighting the impact its investments have had on cancer patients and their families. The report showcases the potential of the organization’s portfolio of 18 companies to improve the lives of over 1.5 million cancer patients. BrightEdge’s Cancer Impact Investing Framework measures the actual and potential impact of the investments it makes in accordance with the American Cancer Society’s mission to end cancer.
BrightEdge LLC’s annual report showcases impact on cancer patients and families
The annual report from BrightEdge LLC, the American Cancer Society’s venture capital and impact investment arm, highlights the positive impact its investments have had on cancer patients and their families. The report reveals that the organization’s portfolio of 18 companies has the potential to improve the lives of over 1.5 million cancer patients. BrightEdge’s investments span the entire cancer journey, from prevention and wellness to diagnosis, treatment, and recovery.
BrightEdge’s Cancer Impact Investing Framework evaluates investment impact
BrightEdge’s Cancer Impact Investing Framework (CIIF) is a proprietary method that evaluates and measures the impact of investments made in accordance with the American Cancer Society’s mission-driven priorities. This framework guides BrightEdge in selecting companies that align with the organization’s goal of ending cancer. By using CIIF, BrightEdge ensures that its investments have both financial and social impact across the cancer care continuum.
BrightEdge invests in four new companies focused on cancer care innovation
In 2022, BrightEdge invested in four new companies that are developing innovative solutions for cancer care. These companies include CellCentric, Paradigm, Vincere Health, and Naveris. Each company focuses on a specific aspect of cancer care, such as improving access to novel treatment options, promoting equitable representation in clinical trials, developing smoking cessation programs, and enabling early cancer detection. These investments further BrightEdge’s goal of accelerating the American Cancer Society’s vision of ending cancer.
BrightEdge’s portfolio companies have raised over $3.1B for cancer-fighting innovations
BrightEdge has invested a total of $28.9 million in its portfolio companies to date, and these companies have collectively raised more than $3.1 billion for their cancer-fighting innovations. This demonstrates the significant financial impact that BrightEdge’s investments have had on the development of treatments, diagnostics, devices, and technologies to combat cancer.
American Cancer Society’s partnership with BrightEdge advances its mission to end cancer
The partnership between the American Cancer Society and BrightEdge is critical to advancing the organization’s mission to end cancer. BrightEdge not only provides alternative funding for the American Cancer Society but also works alongside the organization to accelerate the development of patient-centric therapies and technologies. This partnership has resulted in advancements in scientific research, reduced disparities in cancer care, and built sustainability in the fight against cancer.
BrightEdge’s annual report highlights the positive impact its investments have had on cancer patients and their families. By utilizing its Cancer Impact Investing Framework, BrightEdge ensures that its investments align with the American Cancer Society’s mission to end cancer. The organization’s portfolio companies have raised over $3.1 billion for cancer-fighting innovations, further advancing the fight against cancer. The partnership between the American Cancer Society and BrightEdge is instrumental in achieving the goal of ending cancer as we know it.
Analyst comment
Positive news. The market is expected to respond positively to BrightEdge’s annual report, which showcases the positive impact of their investments on cancer patients and their families. With their Cancer Impact Investing Framework ensuring alignment with the American Cancer Society’s mission, BrightEdge’s investments are likely to attract further funding and support for cancer-fighting innovations. The partnership with the American Cancer Society strengthens their position and contributes to advancements in research, reduced disparities in cancer care, and long-term sustainability in the fight against cancer.
